Foundayo wins UK approval: what actually changed

What the MHRA actually approved

On August 10, 2026, the UK's Medicines and Healthcare products Regulatory Agency cleared Foundayo, Eli Lilly's brand name for orforglipron, for two separate uses: weight management in adults with obesity or overweight, and glycemic control in adults with type 2 diabetes whose blood sugar is not adequately managed on their current regimen. It is the first time any European regulator has authorized orforglipron. The clearance is built on data from two Phase 3 trials, ATTAIN-1 for weight loss and ACHIEVE-1 for diabetes, both of which showed meaningful reductions in body weight and HbA1c against placebo.

This is not the drug's first approval. The FDA cleared Foundayo in the US on April 1, 2026, under the agency's Commissioner's National Priority Voucher pilot, a program built to speed review of drugs the FDA considers a public health priority. That approval came 50 days after Lilly filed, nine months ahead of its original review deadline. The UK decision four months later is the first confirmation that a second major regulator reached the same conclusion on the same data.

Who actually qualifies

The UK indication mirrors the US one closely. For weight management, adults qualify with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition such as high blood pressure or type 2 diabetes, and only alongside a reduced-calorie diet and increased physical activity. It is not a drug prescribed on its own. The diabetes indication is separate and covers adults whose type 2 diabetes remains poorly controlled on existing treatment.

The dosing ladder the MHRA signed off on

Foundayo starts low and climbs slowly. Patients begin at 0.8mg once daily, then move through 2.5mg, 5.5mg, 9mg, 14.5mg, and 17.2mg, spending a minimum of one month at each level before the next increase. That six-step titration is slower than some patients expect from a once-daily pill, but it is the same pattern used with injectable GLP-1s to limit the nausea and GI symptoms that come with a fast ramp-up. The most common side effects listed in the UK label are nausea, constipation, diarrhea, vomiting, dyspepsia, and abdominal pain, concentrated in the first few weeks at each new dose.

Not on the NHS, at least not yet

MHRA approval and NHS availability are two different gates, and it is easy to conflate them. The MHRA only rules on whether a drug is safe and effective enough to be prescribed at all. Before it becomes a routine NHS option, the National Institute for Health and Care Excellence has to separately assess whether it is cost-effective enough to fund at scale, the same hurdle Wegovy and Mounjaro both cleared before wider NHS rollout. That process is ongoing and has no confirmed completion date. Until it wraps, Foundayo in the UK is a private-prescription drug, and once it does clear NICE, patients who are not exempt from prescription charges would pay the standard NHS rate, currently £9.90 per item, a fraction of the private price.

It arrives into a UK market that already has an oral GLP-1

Foundayo is not the first oral GLP-1 the UK has approved this year. Novo Nordisk's Wegovy pill, oral semaglutide, launched there roughly two months earlier. The two drugs solve the same problem in different ways. Semaglutide is a peptide, so the oral version needs an empty stomach, a small sip of water, and a 30-minute wait before eating or taking anything else, or the gut barely absorbs it. Orforglipron is a small molecule, not a peptide, so Foundayo skips that restriction: it can be taken any time of day, with or without food. The tradeoff shows up in the numbers. In trial data, injectable-strength semaglutide at the newer 7.2mg dose posted higher weight loss than orforglipron's top studied dose. For a deeper look at how the two oral drugs actually compare, see our guide on oral semaglutide vs orforglipron.

What changes for patients already on it in the US

Practically, nothing. Foundayo has been available by prescription in the US since April 2026, and the UK decision does not alter US pricing, coverage, or the drug itself. Eli Lilly has said US pricing starts around $149 a month and rises to roughly $399 at higher doses depending on insurance status, and Foundayo is also one of the drugs included under the Medicare GLP-1 Bridge, which brought the out-of-pocket cost down to $50 a month for eligible patients starting July 1, 2026. See our Medicare GLP-1 coverage guide for the eligibility details.

What the UK approval does confirm is that Foundayo's data is holding up under a second regulator's independent review, using the same ATTAIN and ACHIEVE trial results the FDA already reviewed. For patients weighing whether to switch from an injectable GLP-1 to Foundayo, that is a modest but real reassurance. Our guide on switching from an injectable to orforglipron covers what to expect in that transition, including the dosing overlap and what happens to appetite control during the changeover.

What to watch next

Two things determine whether this UK approval turns into wider access. First, the NICE cost-effectiveness review, which decides whether Foundayo becomes an NHS option rather than a private-prescription-only drug. Second, whether other European regulators follow the UK's lead. The European Medicines Agency has not yet ruled on orforglipron for the rest of the EU, and the UK's decision, made independently since Brexit, does not bind it. A broader EU approval, if it comes, would be the next milestone worth tracking, more consequential for Foundayo's global reach than this single-country nod.